https://www.selleckchem.com/pr....oducts/pf-06424439.h
The primary aim was to investigate outcome of the decision making on duration of injection intervals between injection visits over the first 2 years of a treat and extend regimen. Consecutive patients receiving Aflibercept for treatment naïve neovascular age-related macular degeneration between 01.01.2016 and 15.07.2017 were identified from our departmental register. Retrospective data collected on all visits over 24 months were classified into three groups (A) Without Interval Decision Events (IDE)" Injection only" ( IDE resultin